Home » Market
A Game-Changer in Brain Temperature Management
There is a critical, global need for advanced technologies that reduce brain metabolism and oxygen demand—a critical factor in life-threatening conditions such as:
While no dedicated standalone market exists for targeted brain temperature reduction, related segments are already thriving:
Each of these distinct, multi-billion-dollar markets underscores the appetite for better neuroprotection. In conversations with leading neurosurgeons and ICU specialists, the feedback is unanimous: if a precise, non-invasive brain-cooling solution existed, they would use it—but until now, nothing like TEQCool has existed.
Today, TEQCool fills that void—offering the first targeted intranasal system to lower metabolism, control oxygen demand, and prevent secondary injury in the most critical moments. TEQCool’s technology is perfectly positioned to transform existing fields where lowering brain metabolism is already recognized as critical.
Brain metabolism and oxygen demand reduction related markets
TEQCool revolutionizes brain cooling by offering a direct, non-invasive, and highly targeted approach. Unlike traditional cooling systems, TEQCool rapidly and selectively cools the brain via the nasal cavity, leveraging the body’s natural heat exchange system. This enables:
These limitations create a clear and urgent need for a faster, safer, and more targeted solution—which is exactly what TEQCool delivers.
The TEQCool Value Proposition
TEQCool is redefining brain protection with a breakthrough technology that delivers rapid, precise, non-invasive brain cooling—meeting a critical unmet need in neurocritical care.
The TEQCool system will be launched in phases, starting with a research-use-only (RUO) version, which will be FDA-approved/CE-marked for clinical trials and early adopters. This phased approach allows for the collection of crucial clinical data and user feedback.
TEQCool’s non-invasive capabilities will address critical medical needs and have a significant impact on improving patient outcomes. The project’s phased development, combined with the expertise of key partners, positions TEQCool for a successful market introduction, transforming neurocritical care and setting the stage for future expansion into other patient groups.